Phase I-III: Clinical Trials Overview

The 12.5% drop in clinical trials in 2022 mirrors the biopharma industry's struggle with macroeconomic challenges, resulting in a funding crunch. Despite the overall decline, certain sectors experienced growth.

Explore an overview of trial activity, the distribution of trials across disease areas, and key industry sponsors/collaborators to gain insights into the nuanced landscape of clinical trials during this period.